The Core Problem: A Tumor That Hides in Plain Sight
You just had brain surgery. The neurosurgeon told you the resection went well. So why does your care team say you still need six weeks of radiation, followed by chemotherapy?
The answer is in how anaplastic astrocytoma grows. This grade 3 glioma doesn't form a single, enclosed ball that a surgeon can remove in one piece. Instead, individual tumor cells spread along white-matter tracts and blend into tissue that looks normal on an MRI scan. No knife can chase down those scattered cells.
According to the American Association of Neurological Surgeons (AANS), anaplastic astrocytoma "is considered a more malignant evolution of a previously lower-grade astrocytoma, which has acquired more aggressive features, including a higher pace of growth and more invasion into the brain." The AANS is direct about what this means for treatment: surgery is never considered curative for these tumors, and must be followed by radiation and almost always chemotherapy.
This article explains the tumor biology that makes surgery incomplete on its own, what radiation does to leftover disease, how chemotherapy adds another line of attack, and why your molecular profile—especially IDH and MGMT status—shapes your treatment plan.
What Anaplastic Astrocytoma Actually Is
Astrocytomas grow from astrocytes, the star-shaped support cells in the brain. Cleveland Clinic describes a grade 3 astrocytoma as a tumor that requires a combination of surgery, radiation, and chemotherapy for most patients.
The word "anaplastic" means the cells have lost their normal structure. Under a microscope, they show rapid cell division and look clearly abnormal. That cellular chaos drives two key behaviors:
- Fast growth. Tumor cells replicate quickly, so leftover cells can regrow in weeks, not months.
- Diffuse spread. Cells travel along existing brain pathways, reaching far from the visible tumor core. They are microscopic, numerous, and invisible on standard imaging at the time of surgery.
A review in the NIH Bookshelf (Holland-Frei Cancer Medicine) states: "It is impossible to remove all microscopic disease even if there appears to have been a gross total resection on postoperative images, caused by the infiltrative character of these lesions." This is why every patient needs follow-up therapy. The clean post-op MRI doesn't show the full picture.
What Surgery Can—and Cannot—Do
Surgery has real, important goals for anaplastic astrocytoma. The UCSF Brain Tumor Center explains that the primary surgical goal is "maximal safe resection"—removing as much tumor as possible while keeping brain function intact. When tumors sit near areas that control speech or movement, surgeons may use awake surgery with brain mapping to protect those regions.
Here is what surgery achieves:
- Confirms the diagnosis through pathology and molecular testing.
- Reduces tumor burden, which may help later treatments work better.
- Relieves pressure and symptoms caused by the tumor mass.
- Provides tissue for molecular profiling—IDH mutation, MGMT promoter methylation, ATRX status, and more.
Here is what surgery cannot achieve:
- It cannot reach cells that have traveled far from the main tumor into normal-appearing brain.
- It cannot safely remove tumor cells mixed in with neurons that control critical functions.
- It does not eliminate the microscopic leftover disease that is almost always present, even after a complete resection on imaging.
Because of these limits, the National Organization for Rare Disorders (NORD) notes that "because surgery often cannot completely remove a tumor, radiation therapy and chemotherapy are usually used following surgery to continue treatment." This is not a backup plan—it is a planned, necessary part of care.
Why Radiation Is the First Step After Surgery
Radiation therapy typically starts within four to six weeks after surgery. UCLA Health reports that six weeks of radiation therapy usually follows surgery for anaplastic astrocytoma patients.
Radiation works by delivering energy directly into tissue, which damages the DNA of rapidly dividing tumor cells. Because tumor cells divide far more often than most normal brain cells, they accumulate lethal DNA damage while surrounding healthy tissue can repair itself better. Beams are shaped and angled to focus dose on the tumor bed and the margin where invisible cells are likely to be.
The radiation field is designed to cover more than just the visible tumor. It typically includes a margin around the resection cavity to reach the spreading cells that imaging cannot see. This is sometimes called "treating the tumor bed plus margin," and it is why radiation can address leftover microscopic disease that surgery necessarily leaves behind.
It is important to know that radiation is not a simple replacement for surgery and has real side effects. Fatigue, possible cognitive changes over time, and the risk of radiation necrosis are genuine concerns. Your team weighs these carefully against the certainty that untreated leftover tumor cells will regrow. For more details on one common post-radiation problem, see our article on radiation necrosis versus tumor recurrence, which also applies to grade 3 gliomas.
Why Chemotherapy Is Added After Radiation
Radiation treats the local tumor bed. Chemotherapy circulates in the bloodstream and can cross the blood-brain barrier to reach tumor cells throughout the brain. These two therapies attack leftover disease through different methods, which is why combining them works better than either alone.
The standard chemotherapy drug for adult anaplastic astrocytoma is temozolomide (TMZ), an oral medication that damages tumor cell DNA. Cleveland Clinic confirms that the U.S. Food and Drug Administration (FDA) approved temozolomide for adults diagnosed with a grade 3 astrocytoma.
Key clinical trial evidence supports this combination approach. Published analysis in PMC (NIH) describes how the CATNON trial established that treatment of non-codeleted anaplastic astrocytoma consists of maximal safe resection followed by radiotherapy with temozolomide chemotherapy after radiation. This is now widely used for this tumor type.
Other chemotherapy regimens exist as well. PCV (a combination of procarbazine, lomustine, and vincristine) is used in certain situations, particularly in oligodendroglial tumors with 1p/19q codeletion. Research comparing different regimens after surgery found that groups receiving chemotherapy showed significantly longer survival than radiation-only groups—showing the added value of systemic treatment.
How Your Molecular Profile Shapes Your Treatment Plan
Anaplastic astrocytoma is not one single disease. Two patients with the same grade can have very different tumor biology based on their molecular markers. This is why your surgical sample goes to molecular testing immediately after resection.
The two most important markers right now are:
- IDH mutation status. IDH1 or IDH2 mutations are found in many grade 3 gliomas and generally mean a better outlook. The NRG Oncology RTOG 9813 trial found that IDH1-R132H mutation was linked to longer survival in anaplastic astrocytoma patients receiving radiation plus chemotherapy. Research also suggests IDH-mutant tumors may respond better to temozolomide. For a detailed explanation of why IDH status shapes your treatment path, see our article on IDH-mutant glioma versus glioblastoma.
- MGMT promoter methylation. The MGMT gene makes a repair protein that can reverse the DNA damage caused by temozolomide. When the MGMT promoter is methylated (turned off), the tumor cannot repair itself as easily, and TMZ works better. In IDH-wild-type anaplastic gliomas, MGMT methylation status may help guide whether radiation alone or radiation with chemotherapy is better. Learn more about this biomarker in our article on MGMT methylation and temozolomide response.
Other markers—including ATRX mutation, TERT promoter status, and 1p/19q codeletion—provide more detail about the diagnosis and can change the classification of what was historically called anaplastic astrocytoma under older WHO criteria. Since the 2021 WHO classification update, many tumors once labeled grade 3 anaplastic astrocytoma have been reclassified based on molecular data. Your neuro-oncologist will look at all these results together to build your specific treatment plan. For a broader overview of how molecular profiling shapes care, see our article on understanding your GBM and high-grade glioma molecular profile.
The Treatment Sequence: What to Expect After Surgery
For most adults with newly diagnosed anaplastic astrocytoma, the post-surgical sequence looks roughly like this:
- Recovery from surgery (approximately 2–4 weeks). The care team monitors neurological function and reviews final pathology and molecular results.
- Start of radiation therapy. Typically six weeks of external beam radiation to the tumor bed and surrounding margin, five days a week. Temozolomide may be given during this phase depending on molecular profile and hospital protocol.
- Follow-up chemotherapy. After radiation ends, additional cycles of temozolomide or another regimen are often given. The CATNON framework supports post-radiation TMZ for IDH-mutant, non-codeleted tumors.
- MRI surveillance. Regular imaging (typically every two to three months) to check for response or recurrence.
This is a general framework, not a fixed protocol. Your team will customize timing and drugs based on your molecular results, how you're doing, your age, and other clinical factors. If you are within 30 days of diagnosis and feeling overwhelmed by this sequence, our article on what to expect in the first 30 days after a high-grade glioma diagnosis may help.
Integrative Strategies Alongside Standard Care (Not Instead Of)
Some patients and families research integrative or metabolic approaches alongside standard treatment. These can be reasonable topics to discuss with your oncologist. Research into ketogenic diet protocols and metabolic therapies in high-grade gliomas is ongoing, and some patients use these under medical supervision. If you want to learn more about the evidence, see our articles on the ketogenic diet and high-grade glioma and on integrative treatments for glioblastoma and related tumors.
Be clear about this: no integrative or metabolic therapy has trial evidence showing it can replace surgery, radiation, or chemotherapy for anaplastic astrocytoma. When used, these are additions to standard care—not substitutes for it.
Clinical Trials: Additional Options
Standard-of-care treatment—surgery, radiation, chemotherapy—is the proven foundation. But research continues on whether new drugs, immunotherapy approaches, or new treatment sequencing can improve outcomes. Trials such as RTOG 9813 have been key in showing which chemotherapy regimens work best with radiation for anaplastic astrocytoma, and new trials continue to enroll patients.
Ask your neuro-oncologist at your first post-surgical visit whether any open clinical trials match your molecular profile. Trial eligibility is often tied to IDH status, MGMT status, and prior treatment history—all information that comes from your surgical sample. You can search open studies at ClinicalTrials.gov and review options through organizations like the National Brain Tumor Society.
When to Talk to Your Doctor
Speak with your neuro-oncologist or care team right away if:
- You have not yet received your full molecular pathology report (IDH, MGMT, ATRX, 1p/19q) and want to understand what it means for your treatment plan.
- You are more than four weeks post-surgery and radiation has not yet been scheduled.
- You are experiencing new or worsening neurological symptoms, headaches, or seizures after surgery.
- You want to discuss clinical trial eligibility before starting follow-up therapy.
- You are considering any dietary, supplement, or integrative protocol alongside your planned treatment.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.